Full Year
BIVI — FY2026 Annual Financial Report Analysis
BioVie's FY2026 net loss widened 26% to $22.1M as two Phase 2 trials ran in parallel; SUNRISE-PD hit its biomarker endpoint, but $9.0M of cash against $19.0M annual burn means more dilution is coming.